Viridian Therapeutics, Inc.
NASDAQ:VRDNBiotechnology
-$0.15 today
- Market cap
- $3.42B
- Beta
- 0.90
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$3.53
Volume 1.49M
Average 2.86M
VRDN Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Viridian Therapeutics, Inc.NASDAQ: VRDN
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $117K rose 3.5% year over year, ahead of the -3.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.3% from the prior quarter. Over 3 fiscal years it compounded at +21.7% a year.
Context
- Depreciation & amortization amounted to 0.6% of revenue in FY2025, down 178.2 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +3.5% holds above the trailing-twelve-month pace of -3.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 460K USD
- Year-over-year change
- -14.8%
- 4-year CAGR
- +39.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 460K | -14.8% |
| FY2024 | 2024-12-31 | 540K | +3.4% |
| FY2023 | 2023-12-31 | 522K | +104.7% |
| FY2022 | 2022-12-31 | 255K | +112.5% |
| FY2021 | 2021-12-31 | 120K | — |
Depreciation & Amortization vs competitors
How VRDN compares with its peers on the latest reported figures
- VRDN's LTM Jun 2026 depreciation & amortization of $468K is the 3rd highest of the 4 companies compared; the peer median is $2.45M.
- Its year-over-year change of -3.1% is the lowest of 4, against a peer median of +20.3%.
- Depreciation & amortization amounts to 0.7% of revenue for VRDN, versus a peer median of 32.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.63M | +20.3% | +27.0% | 8.9% | |
| LTM Mar 2026 | $2.45M | +41.2% | -1.9% | 32.1% | |
| LTM Jun 2026 | $468K | -3.1% | +21.7% | 0.7% | |
| LTM Mar 2026 | $119.64K | +3.7% | -17.0% | 35.9% | |
| Peer median (excluding VRDN) | $2.45M | +20.3% | -1.9% | 32.1% | |
Competitors are the stored peer set for VRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.96M | 1.77M | 314K | 302K | 70.85M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 2.96M | 1.77M | 314K | 302K | 70.85M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 56.89M | 100.89M | 159.77M | 238.25M | 338.93M |
| Selling, General & Admin | 25.81M | 35.18M | 95M | 61.08M | 95.32M |
| Operating Expenses | 82.69M | 136.08M | 254.76M | 299.34M | 434.24M |
| Depreciation & Amortization | 120K | 255K | 522K | 540K | 460K |
| EBITDA | (79.29M) | (129.13M) | (235.37M) | (266.36M) | (337.19M) |
| EBITDA Margin | -2676.0% | -7287.4% | -74957.0% | -88199.7% | -475.9% |
| Operating Income | (79.73M) | (134.3M) | (254.45M) | (299.04M) | (363.4M) |
| Operating Margin | -2690.8% | -7579.2% | -81035.0% | -99018.2% | -512.9% |
| Interest Income | 318K | 4.92M | 18.56M | 32.13M | 27.4M |
| Interest Expense | 3K | 486K | 1.85M | 3.05M | 4.95M |
| Other Income / Expenses | 315K | 4.43M | 16.72M | 29.09M | 20.79M |
| Income Before Tax | (79.41M) | (129.87M) | (237.73M) | (269.95M) | (342.6M) |
| Pre-Tax Margin | -2680.2% | -7329.2% | -75711.5% | -89387.1% | -483.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (79.41M) | (129.87M) | (237.73M) | (269.95M) | (342.6M) |
| Net Margin | -2680.2% | -7329.2% | -75711.5% | -89387.1% | -483.6% |
| EPS (Basic) | (6.66) | (3.91) | (5.31) | (3.98) | (3.32) |
| EPS (Diluted) | (6.66) | (3.91) | (5.31) | (3.98) | (3.32) |
| Weighted Avg Shares | 11.92M | 32.09M | 44.76M | 67.89M | 84.8M |
| Weighted Avg Shares (Diluted) | 11.92M | 32.09M | 44.76M | 67.89M | 84.8M |
Viridian Therapeutics, Inc.
NASDAQ:VRDN
Intrinsic Alpha fair value
Locked
Current Price
$30.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.